Monoclonal antibody that binds to PCSK9 (proprotein convertase subtilisin/kexin type 9).


LDL-C is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway.


PCSK9 is a serine protease that destroys LDLR in the liver, resulting in decreased LDL-C clearance and increased plasma LDL-C.


PCSK9 inhibitors decrease LDLR degradation by PCSK9, and thereby improve LDL-C clearance and lower plasma LDL-C.

The most important adverse event of Alirocumab is serious hypersensitivity reaction.